68 Stroke / Infarction acute phase non STEMI ASA had significantly worse NIHSS and mRS than those not taking ASA (16 vs. 12 and 5.6 vs. 4.2). Conclusion: Plasma fibrinogen is significantly higher in acute ischemic stroke than in ICH or SAH while there was no significant difference in platelet count and MPV in acute phase. Taking ASA before stroke has slight positive impact on outcome in ischemic stroke but great negative in haemorrhagic stroke. INFARCTION ACUTE PHASE NON STEMI P412 | BEDSIDE Differences in incidence of hospital admissions for acute coronary syndromes in five Western countries U. Zeymer 1 , L. Eckert 2 , I. Dubroca 2 . 1 Institut für Herzinfarktforschung, Ludwigshafen Am Rhein, Germany; 2 Sanofi, Paris, France France Germany Italy Hospitalizations for ACS per given year All ACS types 146,735 340,154 230,198 Hospitalization rate per 100 000 inhabitants ≥18 years STEMI 101 121 146 NSTE-ACS 190 378 323 Proportion by type of ACS, % STEMI 34.6 24.2 31.1 NSTE-ACS 65.4 75.8 68.9 UK USA 150,638 671,260 49 257 77 212 16.2 83.8 26.6 73.4 Conclusions: ACS remains an important cause of hospitalization in the US and Europe despite the advances made in primary and secondary prevention therapies. NSTE-ACS events represent the highest burden, representing almost 3 of every 4 hospitalizations for ACS. Inter-country differences in the ratio of NSTEACS to STEMI need further research. Age (years) Female gender (%) Prior MI (%) Prior PCI (%) Prior CABG (%) Prior stroke (%) Killip 4 (%) Multivessel disease (%) Revascularisation Treatment PCI (%) Hospital Outcome Death MI Stroke No Diab No RF n=8487 Dia + No RF n=3309 No Diab RF + n=520 Diab + RF + n=517 67 34.6 26.0 15.2 5.4 5.2 0.9 64.1 71 42.8 33.9 21.4 8.5 8.1 1.3 72.6 78 31.3 42.0 25.9 11.8 9.6 1.3 75.3 75 35.2 52.0 30.7 15.3 13.0 3.4 85.0 43.4 42.4 39.6 39.7 2.7 1.3 0.4 3.2 1.3 0.5 7.9 2.0 0.5 8.3 2.0 0.6 Abstract P413 – Figure 1 P414 | BEDSIDE Blood transfusion per se does not impact survival in AMI patients. A propensity-score analysis from the French FAST-MI 2005 registry G. Ducrocq 1 , E. Puymirat 2 , N. Danchin 2 , P. Henry 3 , M. Martelet 4 , P.V. Ennezat 5 , F. Schiele 6 , P.G. Steg 1 , J. Ferrieres 7 , T. Simon 8 on behalf of FAST-MI investigators. 1 AP-HP - Hospital Bichat-Claude Bernard, Department of Cardiology, Paris, France; 2 AP-HP - European Hospital Georges Pompidou, Paris, France; 3 AP-HP - Hospital Lariboisiere, Department of Cardiology, Paris, France; 4 General Hospital Langres, Langres, France; 5 Eaux-Claires Clinic, Grenoble, France; 6 University Hospital of Besancon, Besancon, France; 7 University Hospital of Toulouse, Toulouse, France; 8 AP-HP - Hospital Saint Antoine, Paris, France Background and aim: The possible intrinsic toxicity of blood transfusions in patients with acute coronary syndromes is debated. We assessed 5-year mortality according to use of blood transfusion in AMI patients. P413 | BEDSIDE Renal failure but not diabetes determines hospital mortality in patients with NSTE-ACS - results of the Euro heart survey ACS-registry A.K. Gitt 1 , M. Hochadel 2 , W. Wojakowski 3 , U. Zeymer 1 , M. Tendera 3 , F. Schiele 4 , R. Zahn 2 , J.P. Bassand 4 on behalf of Euro Heart Survey ACS Registry Study Group. 1 Herzzentrum Ludwigshafen, Med. Klinik B, Kardiologie + Institut f. Herzinfarktforschung Ludwigshafen, Ludwigshafen am Rhein, Germany; 2 Institut f. Herzinfarktforschung Ludwigshafen, Ludwigshafen am Rhein, Germany; 3 Medical University of Silesia, 1st Department of Cardiology, Katowice, Poland; 4 University Hospital of Besancon - Hospital Jean Minjoz, Department of Cardiology, Besancon, France Background: Patients with NSTE-ACS often have diabetes (Diab) and/or renal failure (RF). It is unclear if RF and Diab are independent predictors of hospital mortality in NSTE-ACS. Methods: In 2006 to 2008, consecutive patients with ACS were enrolled into the EHS-ACS-Registry to document treatment and hospital outcome. We examined the impact of Diab and RF (GFR <60 ml/kg/min) on hospital outcome in patients with NSTE-ACS. Results: Of all ACS, 12,833 presented with NSTE-ACS. Patients with RF were older and more often had concomitant diseases as well as prior myocardial infarctions and coronary interventions independent of the presence of Diab. Patients with RF were less likely to undergo early reperfusion therapy (PCI <48h of symptom onset) as compared to patients without RF. In multivariate analysis, RF but not Diab predicted hospital mortality (p<0.05). Conclusion: In patients with NSTE-ACS, RF outplayed Diab in the prediction of hospital mortality in NSTE-ACS and might be more important in risk stratification than Diab. 5-year survival according to transfusion Downloaded from by guest on October 28, 2014 Aim: Limited global data are available on the incidence of acute coronary syndromes (ACS), and particularly non-ST-elevation acute coronary syndromes (NSTE-ACS). Based on national hospital databases in France, Germany, Italy, UK, and USA, we assessed hospitalization rates for ACS within each country over 1 year. Methods: Patients hospitalized with a principal diagnosis of ACS, NSTE-ACS (including non-ST-elevation myocardial infarction and unstable angina), or STelevation myocardial infarction (STEMI) were identified from admission records in national databases using International Classification of Diseases (ICD) diagnosis codes (ICD-9 for Italy, USA; ICD-10 for France (mapping), Germany, UK). Hospitalizations for ACS were evaluated by country and by comparable age groups available for USA and Germany. Results: Crude hospitalization rates for NSTE-ACS and STEMI varied from 50 to 146/ 100,000 adults and 190 to 378/100,000 adults, respectively. NSTE-ACS comprised 65-84% of hospitalizations for ACS (Table). Age-adjusted hospitalization rates were higher for NSTE-ACS vs. STEMI in all age groups evaluated, particularly in adults aged 65-84 years Age-adjusted hospitalization rates for STEMI and NSTE-ACS were comparable between USA and Germany for all age groups, except for the higher rate of NSTE-ACS hospitalizations in German adults aged 65-84 years. Abstract P413 – Table 1
© Copyright 2024